<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553475</url>
  </required_header>
  <id_info>
    <org_study_id>A0081163</org_study_id>
    <nct_id>NCT00553475</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
  <official_title>Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in
      patients with painful diabetic peripheral neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 1 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 1</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.
Change from baseline: Score at Week 1 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 2 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 2</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.
Change from baseline: Score at Week 2 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 3 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 3</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.
Change from baseline: Score at Week 3 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 4 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 4</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.
Change from baseline: Score at Week 4 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 5 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 5</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.
Change from baseline: Score at Week 5 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 6 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 6</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.
Change from baseline: Score at Week 6 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 7 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 7</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.
Change from baseline: Score at Week 7 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 8 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.
Change from baseline: Score at Week 8 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 9 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 9</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.
Change from baseline: Score at Week 9 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 10 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 10</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.
Change from baseline: Score at Week 10 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 11 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 11</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.
Change from baseline: Score at Week 11 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 12 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.
Change from baseline: Score at Week 12 minus score at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 13 in Mean Weekly Pain Scores</measure>
    <time_frame>From baseline to Week 13</time_frame>
    <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.
Change from baseline: Score at Week 13 minus score at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sleep Interference Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index</measure>
    <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
    <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Week 13 or up to discontinuation</time_frame>
    <description>Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>Week 13 or up to discontinuation</time_frame>
    <description>The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Diabetic Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 300 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 600 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)</description>
    <arm_group_label>Pregabalin 300 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)</description>
    <arm_group_label>Pregabalin 600 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visual Analogue Scale (VAS) of pain is higher than 40 mm.

          -  Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year

        Exclusion Criteria:

          -  Malignancy within the past 2 years.

          -  Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment
             of neuropathy pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Date-shi</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nihonmatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shirakawa-shi</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sukagawa</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ebetu</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaiido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Inashiki</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yatsushiro</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ueda</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yamada</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naha</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tomishiro</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Urazoe</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hirano-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suminoe-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oyama-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arakawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishitokyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ohta-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081163&amp;StudyName=Randomized%2C%20Double-Blind%2C%20Multicenter%2C%20Placebo-Controlled%20Study%20Of%20Pregabalin%20For%20Pain%20Associated%20With%20Diabetic%20Peripheral%20Neuropathy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <results_first_submitted>March 10, 2010</results_first_submitted>
  <results_first_submitted_qc>May 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2010</results_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trials Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After a 1-week baseline phase, subjects were classified into 2 strata based on creatinine clearance (CLcr) values (Low: 30 &lt;CLcr &lt;=60 mL/minute; Normal: CLcr &gt; 60 mL/minute) and were each randomly assigned to 1 of 3 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to moving</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.6"/>
                    <measurement group_id="B2" value="61.3" spread="10.3"/>
                    <measurement group_id="B3" value="62.2" spread="10.3"/>
                    <measurement group_id="B4" value="61.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores</title>
        <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores</title>
          <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.21"/>
                    <measurement group_id="O2" value="-1.82" spread="0.22"/>
                    <measurement group_id="O3" value="-1.94" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment groups and the CLcr strata as factors and baseline values as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0254</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment groups and the CLcr strata as factors and baseline values as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="1.58"/>
                    <measurement group_id="O2" value="2.43" spread="1.59"/>
                    <measurement group_id="O3" value="3.86" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8731</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6337</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="2.47"/>
                    <measurement group_id="O2" value="2.28" spread="2.50"/>
                    <measurement group_id="O3" value="3.97" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4398</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.44</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9153</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.96</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.34" spread="1.97"/>
                    <measurement group_id="O2" value="11.84" spread="1.99"/>
                    <measurement group_id="O3" value="12.89" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4873</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>5.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4008</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.42</ci_lower_limit>
            <ci_upper_limit>8.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="1.44"/>
                    <measurement group_id="O2" value="3.29" spread="1.45"/>
                    <measurement group_id="O3" value="4.40" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5372</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.13</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3480</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>6.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.39"/>
                    <measurement group_id="O2" value="8.06" spread="2.41"/>
                    <measurement group_id="O3" value="11.16" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0544</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>10.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0278</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>15.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="2.52"/>
                    <measurement group_id="O2" value="5.05" spread="2.55"/>
                    <measurement group_id="O3" value="6.35" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7394</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.52</ci_lower_limit>
            <ci_upper_limit>6.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5712</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.49</ci_lower_limit>
            <ci_upper_limit>9.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations</title>
        <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Expected Exposure Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with normal CLcr in the pregabalin 300 mg/day group received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Expected Exposure Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr in the pregabalin 300 and 600 mg/day groups received pregabalin 300 mg/day and subjects with normal CLcr in the pregabalin 600 mg/day group received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations</title>
          <description>Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.16"/>
                    <measurement group_id="O2" value="-1.93" spread="0.17"/>
                    <measurement group_id="O3" value="-1.90" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment groups as factors and baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0333</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment groups as factors and baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders</title>
        <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significance level of 0.05 was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significance level of 0.05 was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 1 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.
Change from baseline: Score at Week 1 minus score at baseline</description>
        <time_frame>From baseline to Week 1</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 1 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.
Change from baseline: Score at Week 1 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.17"/>
                    <measurement group_id="O2" value="-0.82" spread="0.17"/>
                    <measurement group_id="O3" value="-1.14" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0287</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 2 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.
Change from baseline: Score at Week 2 minus score at baseline</description>
        <time_frame>From baseline to Week 2</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 2 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.
Change from baseline: Score at Week 2 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.17"/>
                    <measurement group_id="O2" value="-1.17" spread="0.17"/>
                    <measurement group_id="O3" value="-1.80" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 3 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.
Change from baseline: Score at Week 3 minus score at baseline</description>
        <time_frame>From baseline to Week 3</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 3 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.
Change from baseline: Score at Week 3 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.17"/>
                    <measurement group_id="O2" value="-1.40" spread="0.17"/>
                    <measurement group_id="O3" value="-1.93" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 4 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.
Change from baseline: Score at Week 4 minus score at baseline</description>
        <time_frame>From baseline to Week 4</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 4 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.
Change from baseline: Score at Week 4 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.17"/>
                    <measurement group_id="O2" value="-1.53" spread="0.17"/>
                    <measurement group_id="O3" value="-2.00" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 5 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.
Change from baseline: Score at Week 5 minus score at baseline</description>
        <time_frame>From baseline to Week 5</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 5 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.
Change from baseline: Score at Week 5 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.17"/>
                    <measurement group_id="O2" value="-1.57" spread="0.17"/>
                    <measurement group_id="O3" value="-2.07" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.72</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 6 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.
Change from baseline: Score at Week 6 minus score at baseline</description>
        <time_frame>From baseline to Week 6</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 6 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.
Change from baseline: Score at Week 6 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.17"/>
                    <measurement group_id="O2" value="-1.72" spread="0.17"/>
                    <measurement group_id="O3" value="-2.06" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 7 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.
Change from baseline: Score at Week 7 minus score at baseline</description>
        <time_frame>From baseline to Week 7</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 7 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.
Change from baseline: Score at Week 7 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="0.17"/>
                    <measurement group_id="O2" value="-1.76" spread="0.17"/>
                    <measurement group_id="O3" value="-2.13" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 8 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.
Change from baseline: Score at Week 8 minus score at baseline</description>
        <time_frame>From baseline to Week 8</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 8 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.
Change from baseline: Score at Week 8 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.17"/>
                    <measurement group_id="O2" value="-1.85" spread="0.17"/>
                    <measurement group_id="O3" value="-2.12" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 9 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.
Change from baseline: Score at Week 9 minus score at baseline</description>
        <time_frame>From baseline to Week 9</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 9 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.
Change from baseline: Score at Week 9 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.17"/>
                    <measurement group_id="O2" value="-1.93" spread="0.17"/>
                    <measurement group_id="O3" value="-2.06" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 10 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.
Change from baseline: Score at Week 10 minus score at baseline</description>
        <time_frame>From baseline to Week 10</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 10 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.
Change from baseline: Score at Week 10 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.17"/>
                    <measurement group_id="O2" value="-1.93" spread="0.18"/>
                    <measurement group_id="O3" value="-2.10" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 11 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.
Change from baseline: Score at Week 11 minus score at baseline</description>
        <time_frame>From baseline to Week 11</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 11 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.
Change from baseline: Score at Week 11 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="0.17"/>
                    <measurement group_id="O2" value="-1.95" spread="0.18"/>
                    <measurement group_id="O3" value="-2.09" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0105</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 12 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.
Change from baseline: Score at Week 12 minus score at baseline</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 12 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.
Change from baseline: Score at Week 12 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.17"/>
                    <measurement group_id="O2" value="-2.01" spread="0.18"/>
                    <measurement group_id="O3" value="-2.13" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="1.92"/>
                    <measurement group_id="O2" value="4.20" spread="1.94"/>
                    <measurement group_id="O3" value="12.87" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6118</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.23</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>13.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health</title>
        <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health</title>
          <description>The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="1.83"/>
                    <measurement group_id="O2" value="5.33" spread="1.85"/>
                    <measurement group_id="O3" value="7.81" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4602</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.47</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1625</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>9.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sleep Interference Scores</title>
        <description>The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sleep Interference Scores</title>
          <description>The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.18"/>
                    <measurement group_id="O2" value="-1.59" spread="0.18"/>
                    <measurement group_id="O3" value="-1.36" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0273</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores</title>
        <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores</title>
          <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="0.50"/>
                    <measurement group_id="O2" value="-4.60" spread="0.50"/>
                    <measurement group_id="O3" value="-4.95" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.87</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.65</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores</title>
        <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores</title>
          <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.20"/>
                    <measurement group_id="O2" value="-1.43" spread="0.20"/>
                    <measurement group_id="O3" value="-1.39" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0068</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0707</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores</title>
        <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores</title>
          <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="0.66"/>
                    <measurement group_id="O2" value="-6.03" spread="0.66"/>
                    <measurement group_id="O3" value="-6.36" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.76</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0087</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.67</ci_lower_limit>
            <ci_upper_limit>-0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores</title>
        <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores</title>
          <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.92" spread="2.38"/>
                    <measurement group_id="O2" value="-24.19" spread="2.40"/>
                    <measurement group_id="O3" value="-24.41" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.40</ci_lower_limit>
            <ci_upper_limit>-2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0427</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.74</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores</title>
        <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores</title>
          <description>The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.09"/>
                    <measurement group_id="O2" value="-0.80" spread="0.09"/>
                    <measurement group_id="O3" value="-0.96" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0365</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.03" spread="1.86"/>
                    <measurement group_id="O2" value="-15.40" spread="1.88"/>
                    <measurement group_id="O3" value="-12.81" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.38</ci_lower_limit>
            <ci_upper_limit>-2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1907</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.45</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="2.51"/>
                    <measurement group_id="O2" value="-5.96" spread="2.53"/>
                    <measurement group_id="O3" value="-1.56" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9905</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.37</ci_lower_limit>
            <ci_upper_limit>5.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2532</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.19</ci_lower_limit>
            <ci_upper_limit>12.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.69"/>
                    <measurement group_id="O2" value="-3.02" spread="1.71"/>
                    <measurement group_id="O3" value="-4.47" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4538</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2782</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.97</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.12"/>
                    <measurement group_id="O2" value="0.69" spread="0.12"/>
                    <measurement group_id="O3" value="0.54" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3661</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="2.61"/>
                    <measurement group_id="O2" value="17.69" spread="2.64"/>
                    <measurement group_id="O3" value="21.73" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0511</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>11.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>17.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="2.17"/>
                    <measurement group_id="O2" value="0.83" spread="2.19"/>
                    <measurement group_id="O3" value="4.83" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1123</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>8.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0206</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>14.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index</title>
        <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>From baseline to Week 13 or up to study discontinuation (Study Endpoint)</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index</title>
          <description>The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.91" spread="1.45"/>
                    <measurement group_id="O2" value="-11.45" spread="1.46"/>
                    <measurement group_id="O3" value="-9.73" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0269</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.67</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4183</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.24</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change</title>
        <description>Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient’s overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
        <time_frame>Week 13 or up to discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change</title>
          <description>Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient’s overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.2"/>
                    <measurement group_id="O2" value="2.9" spread="1.1"/>
                    <measurement group_id="O3" value="2.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0148</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change</title>
        <description>The Patient Global Impression of Change is a patient-rated instrument that measures change in patient’s overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
        <time_frame>Week 13 or up to discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change</title>
          <description>The Patient Global Impression of Change is a patient-rated instrument that measures change in patient’s overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                    <measurement group_id="O2" value="3.2" spread="1.0"/>
                    <measurement group_id="O3" value="2.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0818</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 13 in Mean Weekly Pain Scores</title>
        <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.
Change from baseline: Score at Week 13 minus score at baseline</description>
        <time_frame>From baseline to Week 13</time_frame>
        <population>Full analysis set. Observed case (No imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 13 in Mean Weekly Pain Scores</title>
          <description>The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.
Change from baseline: Score at Week 13 minus score at baseline</description>
          <population>Full analysis set. Observed case (No imputation).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.17"/>
                    <measurement group_id="O2" value="-2.04" spread="0.18"/>
                    <measurement group_id="O3" value="-2.12" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>Mixed Model Repeated Measures Analysis</method>
            <method_desc>Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

